LONDON Bowing to the inevitable, industry bodies in the UK have collaborated with payers and regulators in publishing a guide to biosimilars, to inform staff in the National Health Service (NHS) on their adoption.
The guide described by the NHS as the "authoritative source of reference" is claimed to be the first consensual summary on the properties of biosimilars and factors to consider in their use to be published at a country level. Its publication comes as the first biosimilar of a big-selling monoclonal antibody, Remicade (infliximab, Johnson & Johnson), is starting to transform market dynamics.
The chief pharmaceutical officer for NHS England, Keith Ridge, said as the number of biosimilars increases, the health service needs to plan for their timely, appropriate and cost-effective introduction.
"All staff in the NHS, from senior managers to commissioners, through to front-line health professionals,